Tsutomu Shimada

Dr. Tsutomu Shimada


Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1994 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
TSTsutomu Shimada
Tsutomu Shimada
HYHiroshi Yamazaki
Hiroshi Yamazaki
MMM Mimura
M Mimura
YIY Inui
Y Inui
FGF P Guengerich
F P Guengerich

1 July 1991 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
FGF. Peter Guengerich
F. Peter Guengerich
TSTsutomu Shimada
Tsutomu Shimada


1 January 2006 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
TSTsutomu Shimada
Tsutomu Shimada
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental carcinogens and metabolized by a variety of xenobiotic-metabolizing enzymes such as cytochrome P450 (P450 or CYP), epoxide hydrolase, glutathione transferase, UDP-glucuronosyltransferase, sulfotransferase, NAD(P)H quinone oxidoreductase 1, and aldo-keto reductase. These enzymes mainly participate in the conversion of PAHs to more polar and water-soluble metabolites, and the resultant metabolites are readily excreted from the body. However, during the course of metabolism, a variety of unstable and reactive intermediates of PAHs are formed, and these metabolites attack DNA, causing cell toxicity and transformation. P450s and epoxide hydrolase convert PAHs to proximate carcinogenic metabolites, PAH-diols, and these products are further metabolized by P450s to ultimate carcinogenic metabolites, PAH diol-epoxides, or by aldo-keto reductase to reactive PAH o-quinones. PAHs are also activated by P450 and peroxidases to reactive radical cations that bind covalently to DNA. The oxygenated and reactive metabolites of PAHs are usually converted to more polar and detoxified products by phase II enzymes. Inter-individual differences exist in levels of expression and catalytic activities of a variety of enzymes that activate and/or detoxify PAHs in various organs of humans and these phenomena are thought to be critical in understanding the basis of individual differences in response to PAHs. Factors affecting such variations include induction and inhibition of enzymes by diverse chemicals and, more importantly, genetic polymorphisms of enzymes in humans.

1 October 1992 in Carcinogenesis
Verified
Journal Article
Closed access
PDF file
HYHiroshi Yamazaki
Hiroshi Yamazaki
YIYukiharu Inui
Yukiharu Inui
CYChul-Ho Yun
Chul-Ho Yun
FGF.Peter Guengerich
F.Peter Guengerich
TSTsutomu Shimada
Tsutomu Shimada
An acetyltransferase-overexpressing strain of Salmonella typhimurium (NM2009) has been used to investigate roles of human liver microsomal cytochrome P450 (P450) enzymes in the activation of carcinogenic nitrosamine derivatives, including N-nitrosodialkylamines and tobacco-smoke-related nitrosamines, to genotoxic products. Studies employing correlation of activities with several P450-dependent monooxygenase reactions in different human liver samples, inhibition of microsomal activities by antibodies raised against human P450 enzymes and by specific P450 inhibitors, and reconstitution of activities with purified P450 enzymes suggest that the tobacco-smoke-related nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and N-nitrosonornicotine (NNN) as well as N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) are oxidized to genotoxic products by different P450 enzymes, particularly P450 2E1 and 2A6. The activation of NDMA and NNN by liver microsomes was suggested to be catalyzed more actively by P450 2E1 than by other P450 enzymes because the activities were well correlated with NDMA N-demethylation and aniline p-hydroxylation in different human samples, and purified P450 2E1 had the highest activities in reconstituted monooxygenase systems. The relatively high contribution of P450 2A6 to the activation of NDEA and NNK was supported by the correlation seen with coumarin 7-hydroxylation in human liver microsomes, and antibodies raised against P450 2A6 inhibited both activities by ˜50%. P450 3A4, 2D6 and 2C enzymes appear not to be extensively involved in the activation of these nitrosamines as judged by several criteria examined. Thus, this work indicates that several P450 enzymes, particularly P450 2E1 and 2A6, catalyze metabolic activation of nitrosamine derivatives including N-nitroso-dialkylamines and tobacco-smoke-related nitrosamines in human liver microsomes.

1 June 1998 in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
Verified
Journal Article
Closed access
FGF.PEter Guengerich
F.PEter Guengerich
WJWilliam W. Johnson
William W. Johnson
TSTsutomu Shimada
Tsutomu Shimada
YUYune-Fang Ueng
Yune-Fang Ueng
HYHiroshi Yamazaki
Hiroshi Yamazaki
SLSophie Langouët
Sophie Langouët